ArticleCancer control : journal of the Moffitt Cancer Center
Leveraging Machine Learning Models to Explore Disparities in Prostate Cancer Diagnosis, Treatment, and Survival.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
IntroductionProstate cancer (CaP) is the second most common cancer in men globally and a leading cause of cancer-related mortality, particularly among older men. In the United States, disparities in incidence, stage at diagnosis, and outcomes persist across racial, socioeconomic, and geographic lines. Men in medically underserved regions like Appalachia experience higher mortality due to limited access to timely screening and treatment. Given the complex interplay of clinical, behavioral, and sociodemographic factors, machine learning (ML) offers promise in identifying survival predictors that traditional models may overlook. This study applies ML models to assess the impact of age at diagnosis, treatment modality, and other sociodemographic and clinical factors on CaP survival outcomes using data from the Kentucky Cancer Registry (KCR).MethodsWe retrospectively analyzed 37 893 CaP cases diagnosed from 2010 to 2022 using KCR data linked to mortality records. Kaplan-Meier (KM), Random Survival Forest (RSF), and Elastic Net regression were used to estimate survival, assess variable importance, and evaluate predictive performance. Missing data were handled via multiple imputation, and leave-one-out cross-validation minimized overfitting. Models were compared using out-of-bag error, continuous ranked probability scores (CRPS), and interpretability.ResultsML models identified age at diagnosis, treatment modality, and smoking status as the top survival predictors. RSF showed that age was approximately 2.5 times more influential than treatment type. Patients diagnosed before age 60 were more likely to undergo surgery and had lower mortality, while older men more often received non-surgical therapies and experienced worse outcomes. Insurance status, tumor grade, lymph node involvement, and marital status also affected survival, with pronounced disparities among uninsured and government-insured patients.ConclusionsML models highlighted age, smoking, and treatment type as key predictors of CaP survival. Findings support early screening, equitable treatment access, and behavioral health integration to reduce disparities in high-risk areas such as Kentucky and Appalachia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.